Literature DB >> 32924633

Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study.

Aisha T Langford1,2,3,4,5,6,7,8,9,10,11, Oluwasegun P Akinyelure1,2,3,4,5,6,7,8,9,10,11, Tony L Moore1,2,3,4,5,6,7,8,9,10,11, George Howard1,2,3,4,5,6,7,8,9,10,11, Yuan-I Min1,2,3,4,5,6,7,8,9,10,11, William B Hillegass1,2,3,4,5,6,7,8,9,10,11, Adam P Bress1,2,3,4,5,6,7,8,9,10,11, Gabriel S Tajeu1,2,3,4,5,6,7,8,9,10,11, Mark Butler1,2,3,4,5,6,7,8,9,10,11, Byron C Jaeger1,2,3,4,5,6,7,8,9,10,11, Yuichiro Yano1,2,3,4,5,6,7,8,9,10,11, Daichi Shimbo1,2,3,4,5,6,7,8,9,10,11, Gbenga Ogedegbe1,2,3,4,5,6,7,8,9,10,11, David Calhoun1,2,3,4,5,6,7,8,9,10,11, John N Booth1,2,3,4,5,6,7,8,9,10,11, Paul Muntner1,2,3,4,5,6,7,8,9,10,11.   

Abstract

Resistant hypertension, defined as blood pressure levels above goal while taking ≥3 classes of antihypertensive medication or ≥4 classes regardless of blood pressure level, is associated with increased cardiovascular disease risk. The 2018 American Heart Association Scientific Statement on Resistant Hypertension recommends healthy lifestyle habits and thiazide-like diuretics and mineralocorticoid receptor antagonists for adults with resistant hypertension. The term apparent treatment-resistant hypertension (aTRH) is used when pseudoresistance cannot be excluded. We estimated the use of healthy lifestyle factors and recommended antihypertensive medication classes among US Black adults with aTRH. Data were pooled for Black participants in the JHS (Jackson Heart Study) in 2009 to 2013 (n=2496) and the REGARDS study (Reasons for Geographic and Racial Differences in Stroke) in 2013 to 2016 (n=3786). Outcomes included lifestyle factors (not smoking, not consuming alcohol, ≥75 minutes of vigorous-intensity or ≥150 minutes of moderate or vigorous physical activity per week, and body mass index <25 kg/m2) and recommended antihypertensive medications (thiazide-like diuretics and mineralocorticoid receptor antagonists). Overall, 28.3% of participants who reported taking antihypertensive medication had aTRH. Among participants with aTRH, 14.5% and 1.2% had ideal levels of 3 and 4 of the lifestyle factors, respectively. Also, 5.9% of participants with aTRH reported taking a thiazide-like diuretic, and 9.8% reported taking a mineralocorticoid receptor antagonist. In conclusion, evidence-based lifestyle factors and recommended pharmacological treatment are underutilized in Black adults with aTRH. Increased use of lifestyle recommendations and antihypertensive medication classes specifically recommended for aTRH may improve blood pressure control and reduce cardiovascular disease-related morbidity and mortality among US Black adults. Graphic Abstract A graphic abstract is available for this article.

Entities:  

Keywords:  African continental ancestry group; antihypertensive agents; blood pressure; health behavior; hypertension

Mesh:

Substances:

Year:  2020        PMID: 32924633      PMCID: PMC7685176          DOI: 10.1161/HYPERTENSIONAHA.120.14836

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

Review 1.  Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond.

Authors:  Donald M Lloyd-Jones; Yuling Hong; Darwin Labarthe; Dariush Mozaffarian; Lawrence J Appel; Linda Van Horn; Kurt Greenlund; Stephen Daniels; Graham Nichol; Gordon F Tomaselli; Donna K Arnett; Gregg C Fonarow; P Michael Ho; Michael S Lauer; Frederick A Masoudi; Rose Marie Robertson; Véronique Roger; Lee H Schwamm; Paul Sorlie; Clyde W Yancy; Wayne D Rosamond
Journal:  Circulation       Date:  2010-01-20       Impact factor: 29.690

Review 2.  Pathophysiology and treatment implications of hypertension in the African-American population.

Authors:  M Rahman; J G Douglas; J T Wright
Journal:  Endocrinol Metab Clin North Am       Date:  1997-03       Impact factor: 4.741

3.  Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Paul Muntner; Barry R Davis; William C Cushman; Sripal Bangalore; David A Calhoun; Sara L Pressel; Henry R Black; John B Kostis; Jeffrey L Probstfield; Paul K Whelton; Mahboob Rahman
Journal:  Hypertension       Date:  2014-08-04       Impact factor: 10.190

4.  Prevalence of Apparent Treatment-Resistant Hypertension in the United States.

Authors:  Robert M Carey; Swati Sakhuja; David A Calhoun; Paul K Whelton; Paul Muntner
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

Review 5.  Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.

Authors:  George C Roush; Michael E Ernst; John B Kostis; Suraj Tandon; Domenic A Sica
Journal:  Hypertension       Date:  2015-03-02       Impact factor: 10.190

6.  Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.

Authors:  Michael P Dorsch; Brenda W Gillespie; Steven R Erickson; Barry E Bleske; Alan B Weder
Journal:  Hypertension       Date:  2011-03-07       Impact factor: 10.190

7.  Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study.

Authors:  Keith M Diaz; John N Booth; David A Calhoun; Marguerite R Irvin; George Howard; Monika M Safford; Paul Muntner; Daichi Shimbo
Journal:  Hypertension       Date:  2014-06-09       Impact factor: 10.190

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010.

Authors:  Valy Fontil; Mark J Pletcher; Raman Khanna; David Guzman; Ronald Victor; Kirsten Bibbins-Domingo
Journal:  J Gen Intern Med       Date:  2013-11-19       Impact factor: 5.128

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more
  4 in total

1.  Nephrotic Syndrome Complications - New and Old. Part 1.

Authors:  Ruxandra Mihaela Busuioc; Gabriel Mircescu
Journal:  Maedica (Bucur)       Date:  2022-03

2.  Blood pressure control in hypertensive patients attending a rural community health centre in Gauteng Province, South Africa: A cross-sectional study.

Authors:  Sergius C Onwukwe; Nnabuike C Ngene
Journal:  S Afr Fam Pract (2004)       Date:  2022-03-28

3.  Blood Pressure Control Among Non-Hispanic Black Adults Is Lower Than Non-Hispanic White Adults Despite Similar Treatment With Antihypertensive Medication: NHANES 2013-2018.

Authors:  Donald K Hayes; Sandra L Jackson; Yanfeng Li; Gregory Wozniak; Stavros Tsipas; Yuling Hong; Angela M Thompson-Paul; Hilary K Wall; Cathleen Gillespie; Brent M Egan; Matthew D Ritchey; Fleetwood Loustalot
Journal:  Am J Hypertens       Date:  2022-06-16       Impact factor: 3.080

Review 4.  Guideline-Driven Management of Hypertension: An Evidence-Based Update.

Authors:  Robert M Carey; Jackson T Wright; Sandra J Taler; Paul K Whelton
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.